Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC

Merck has struck a deal to buy VelosBio for $2.75 billion. The takeover will give Merck control of an antibody-drug conjugate (ADC) that caused complete responses in 80% of previously treated diffuse large B-cell lymphoma (DLBCL) patients in a small clinical trial.